Uterine Artery Embolization for Pedunculated Subserosal Leiomyomas: Evidence of Safety and Efficacy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yong Seek | - |
dc.contributor.author | Han, Kichang | - |
dc.contributor.author | Kim, Man-Deuk | - |
dc.contributor.author | Kim, Gyoung Min | - |
dc.contributor.author | Kwon, Joon Ho | - |
dc.contributor.author | Lee, Junhyung | - |
dc.contributor.author | Choi, Woosun | - |
dc.contributor.author | Won, Jong Yun | - |
dc.contributor.author | Lee, Do Yun | - |
dc.date.accessioned | 2024-02-05T06:00:46Z | - |
dc.date.available | 2024-02-05T06:00:46Z | - |
dc.date.issued | 2018-04 | - |
dc.identifier.issn | 1051-0443 | - |
dc.identifier.issn | 1535-7732 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/71767 | - |
dc.description.abstract | Purpose: To evaluate safety and efficacy of uterine artery embolization (UAE) for pedunculated subserosal (PS) leiomyomas. Materials and Methods: Of 1,069 patients who underwent UAE for symptomatic leiomyomas or adenomyosis from 2007 to 2016, 55 patients (mean age 40.3 y +/- 4.8) with 66 PS leiomyomas (mean diameter 6.61 cm +/- 2.04) were enrolled. Each PS leiomyoma was categorized into 1 of 2 groups: high-risk PS leiomyoma (stalk diameter < 25% of diameter of leiomyoma) and low-risk PS leiomyoma (stalk diameter 25%-50% of diameter of leiomyoma). MR imaging was performed 3 months after UAE. Rates of infarction and volume reduction were compared between PS leiomyomas and non-PS dominant leiomyomas and between high-risk and low-risk PS leiomyomas. Complications related to PS leiomyomas were assessed. Results: At a median follow-up of 96 days (range, 36-348 d) after UAE, none of the patients (0%) had complications related to PS leiomyomas, even among high-risk cases. Mean volume reductions of 38.2% and 38.4% were achieved for PS leiomyomas and non-PS dominant leiomyomas, respectively (P = .953). There were 3 (5.5%) minor adverse events, but none were related to PS leiomyoma. There was no significant difference in volume reduction and infarction rates between low-risk and high-risk PS leiomyomas. Conclusions: UAE is safe and effective in patients with PS leiomyomas even for high-risk cases (stalk diameter < 25% of diameter of leiomyoma). PS leiomyoma should not be considered a contraindication for UAE. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | ELSEVIER SCIENCE INC | - |
dc.title | Uterine Artery Embolization for Pedunculated Subserosal Leiomyomas: Evidence of Safety and Efficacy | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jvir.2017.11.022 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, v.29, no.4, pp 497 - 501 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000428609700009 | - |
dc.identifier.scopusid | 2-s2.0-85042255452 | - |
dc.citation.endPage | 501 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 497 | - |
dc.citation.title | JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY | - |
dc.citation.volume | 29 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordPlus | SYMPTOMATIC LEIOMYOMATA | - |
dc.subject.keywordPlus | FIBROIDS | - |
dc.subject.keywordPlus | COMPLICATIONS | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.